Corporate Banner
Satellite Banner
Immunology
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

S-TARget Achieves In Vivo Proof of Concept for Its Allergy Vaccine SG100

Published: Monday, April 08, 2013
Last Updated: Monday, April 08, 2013
Bookmark and Share
SG100 is being developed for the prevention and therapy of severe allergic asthma caused by house dust mite (HDM) allergens.

In a study of SG100 in naïve rhesus monkeys, S-TARget has demonstrated that repeated injections of the candidate vaccine induced a Th1 cell mediated memory immune response against natural HDM allergens. A Th1 immune response is considered a “healthy” immune response to allergens. By contrast, a Th2-mediated immune response can lead to allergic diseases—which in the case of exposure to HDM allergens include severe and persistent asthma. The study has also shown that SG100 can be safely applied in a relevant animal model.

“We are excited about the data from this study as it shows that S-TARget’s technology platform is safe and efficacious in a highly relevant animal model”, commented Geert Mudde, PhD, Chief Scientific Officer of S-TARget and Co-founder of the company.

Dr Mudde continued: “Based on this proof-of-concept study, we are currently initiating a follow-on study with SG100 in a clinically highly predictive non human primate animal model of house dust mite induced allergic asthma. The goal is to demonstrate the ability of SG100 to not only induce a Th1-mediated immune response, but to remodel existing ‘allergic’ Th2 cells into ‘healthy’ Th1 cells, thus triggering a normal immune response to future HDM exposure. SG100 is specifically designed for the human immune system (it will not work in rodents) to achieve exactly this remodeling of allergic Th2-cells. Such remodeling will provide a powerful therapeutic approach to directly address the causes of allergic diseases instead of just treating the symptoms”.

Follow-on study to reduce development risk; data expected in July

“The encouraging results achieved with SG100 are a major milestone for S-TARget”, commented Christof Langer, MBA, Chief Executive Officer and Co-founder of S-TARget. “We look forward to conducting the follow-on study of SG100 as it will be highly predictive of its subsequent development in the clinic. We believe that this approach will facilitate the clinical development. Moreover, it will significantly reduce the development risk of this program, making S-TARget an attractive target for future investors.” S-TARget expects the results of this study to be available in July 2013.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,100+ scientific posters on ePosters
  • More than 4,500+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.


Scientific News
Alzheimer’s Protein Serves as Natural Antibiotic
Alzheimer's-associated amyloid plaques may be part of natural process to trap microbes, findings suggest new therapeutic strategies.
Slime Mold Reveals Clues to Immune Cells’ Directional Abilities
Study from UC San Diego identifies a protein involved in the directional ability of a slime mold.
Supressing Intenstinal Analphylaxis in Peanut Allergy
Study from National Jewish Health shows that blockade of histamine receptors suppresses intestinal anaphylaxis in peanut allergy.
Getting a Better Look at How HIV Infects and Takes Over its Host Cells
A new approach, developed by a team of researchers led by The Rockefeller University and The Aaron Diamond AIDS Research Center (ADARC), offers an unprecedented view of how a virus infects and appropriates a host cell, step by step.
Untangling Disease-Related Protein Misfolding
Work advances understanding of genetic forms of thrombosis, emphysema, cirrhosis of the liver, neurodegenerative diseases and inflammation, among others.
Developing a More Precise Seasonal Flu Vaccine
During the 2014-15 flu season, the poor match between the virus used to make the world’s vaccine stocks and the circulating seasonal virus yielded a vaccine that was less than 20 percent effective.
Fighting Cancer with Borrowed Immunity
A new step in cancer immunotherapy: researchers from the Netherlands Cancer Institute and University of Oslo/Oslo University Hospital show that even if one's own immune cells cannot recognize and fight their tumors, someone else's immune cells might.
Loss Of Y Chromosome Increases Risk Of Alzheimer’s
Men with blood cells that do not carry the Y chromosome are at greater risk of being diagnosed with Alzheimer’s disease. This is in addition to an increased risk of death from other causes, including many cancers. These new findings by researchers at Uppsala University could lead to a simple test to identify those at risk of developing Alzheimer’s disease.
Immune Cells Remember Their First Meal
Scientists at the University of Bristol have identified the trigger for immune cells' inflammatory response – a discovery that may pave the way for new treatments for many human diseases.
"Sunscreen" Gene May Guard Against Melanoma
USC-led study reveals that melanoma patients with deficient or mutant copies of the gene are less protected from harmful ultraviolet rays.
SELECTBIO

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,100+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,500+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!